Shares of Nektar Therapeutics and Mineralys Therapeutics have surged, with Nektar developing an experimental eczema treatment and Mineralys working on an experimental drug for high blood pressure. Nektar’s stock rose by 108% due to promising results in a phase 2b study for their eczema treatment, showing potential to compete with a blockbuster drug. Mineralys’ stock soared by 155% after reporting positive clinical trial results for their hypertension treatment. Mineralys plans to file an application with the FDA by late 2025 or early 2026. Both stocks have high potential for growth but also carry risks.

Read more at Yahoo Finance: These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?